• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在日本人群中常见的多种II类主要组织相容性复合体分子所呈递的新型NY-ESO-1混杂辅助表位的鉴定。

Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population.

作者信息

Ohkuri Takayuki, Sato Masayoshi, Abe Hiroyuki, Tsuji Keiko, Yamagishi Yuka, Ikeda Hiroaki, Matsubara Naoki, Kitamura Hidemitsu, Nishimura Takashi

机构信息

Division of Immunoregulation, Section of Disease Control, Hokkaido University, Sapporo, Japan.

出版信息

Cancer Sci. 2007 Jul;98(7):1092-8. doi: 10.1111/j.1349-7006.2007.00501.x. Epub 2007 May 4.

DOI:10.1111/j.1349-7006.2007.00501.x
PMID:17488334
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11158738/
Abstract

NY-ESO-1 is a cancer-testis antigen that elicits strong cellular and humoral immune responses against NY-ESO-1-expressing tumors. Although CD4(+) T cells play a critical role in inducing antitumor immunity, little is known about MHC class II-restricted helper epitopes of the NY-ESO-1 antigen compared with MHC class I-restricted epitopes. Here, we searched for new NY-ESO-1 helper epitopes presented by MHC class II molecules, especially those found frequently in the Japanese population. We established five NY-ESO-1-specific helper T-cell lines from healthy Japanese donors using NY-ESO-1 recombinant protein and peptide. Using MHC class II-specific antibodies and a panel of Epstein-Barr virus-transformed B-cell lines, it was demonstrated that four out of the five T-cell lines recognized a region within NY-ESO-1(119-143) in the context of HLA-DRB10802, DRB10901, DRB11502 or DRB10405/*0410. In addition, using a set of overlapping 15-mer synthetic peptides, we found that NY-ESO-1(122-138) was a promiscuous region that bound to four distinct HLA-DR molecules found in the Japanese population. These findings expand the usefulness of NY-ESO-1 as a tool for tumor vaccine therapy in eliciting NY-ESO-1-specific helper T-cell responses, especially in Japanese cancer patients.

摘要

NY-ESO-1是一种癌胚抗原,可引发针对表达NY-ESO-1的肿瘤的强烈细胞免疫和体液免疫反应。尽管CD4(+) T细胞在诱导抗肿瘤免疫中起关键作用,但与MHC I类限制性表位相比,关于NY-ESO-1抗原的MHC II类限制性辅助表位知之甚少。在此,我们寻找由MHC II类分子呈递的新的NY-ESO-1辅助表位,尤其是在日本人群中频繁发现的表位。我们使用NY-ESO-1重组蛋白和肽从健康日本供体中建立了五个NY-ESO-1特异性辅助性T细胞系。使用MHC II类特异性抗体和一组爱泼斯坦-巴尔病毒转化的B细胞系,证明五个T细胞系中的四个在HLA-DRB10802、DRB10901、DRB11502或DRB10405/*0410的背景下识别NY-ESO-1(119-143)内的一个区域。此外,使用一组重叠的15聚体合成肽,我们发现NY-ESO-1(122-138)是一个混杂区域,可与日本人群中发现的四种不同的HLA-DR分子结合。这些发现扩展了NY-ESO-1作为肿瘤疫苗治疗工具在引发NY-ESO-1特异性辅助性T细胞反应方面的用途,特别是在日本癌症患者中。

相似文献

1
Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population.在日本人群中常见的多种II类主要组织相容性复合体分子所呈递的新型NY-ESO-1混杂辅助表位的鉴定。
Cancer Sci. 2007 Jul;98(7):1092-8. doi: 10.1111/j.1349-7006.2007.00501.x. Epub 2007 May 4.
2
Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.由HLA-DQ B1 03011递呈的、可被CD4+ T细胞识别的新型NY-ESO-1表位的鉴定。
Int J Cancer. 2006 Feb 1;118(3):668-74. doi: 10.1002/ijc.21391.
3
Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.鉴定由人类组织相容性抗原(HLA)-DRB4*0101-0103呈递、并被表达NY-ESO-1的黑色素瘤患者的CD4(+) T淋巴细胞识别的NY-ESO-1表位。
J Exp Med. 2000 Feb 21;191(4):625-30. doi: 10.1084/jem.191.4.625.
4
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.NY-ESO-1 119-143是一种可被Th1型和Th2型肿瘤反应性CD4 + T细胞识别的多反应性主要组织相容性复合体II类T辅助表位。
Cancer Res. 2002 Jan 1;62(1):213-8.
5
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.一种源自NY-ESO-1的表位,它能与多种HLA-DR和HLA-DP4分子发生混杂结合,并刺激来自表达NY-ESO-1的黑色素瘤患者的自体CD4+ T细胞。
J Immunol. 2005 Feb 1;174(3):1751-9. doi: 10.4049/jimmunol.174.3.1751.
6
The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.LAGE-1的可变开放阅读框产生了多个混杂的、受HLA-DR限制的表位,这些表位可被辅助性T细胞1型肿瘤反应性CD4 + T细胞识别。
Cancer Res. 2003 Oct 1;63(19):6506-15.
7
Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.NY-ESO-1 肽/DRB1*08:03 四聚体的制备及疫苗接种癌症患者体内 CD4 T 细胞反应的体外检测。
Vaccine. 2014 Feb 12;32(8):957-64. doi: 10.1016/j.vaccine.2013.12.042. Epub 2014 Jan 5.
8
Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.用重组NY-ESO-1蛋白进行疫苗接种可引发具有保守T细胞受体库的免疫显性HLA-DR52b限制性CD4 + T细胞反应。
Clin Cancer Res. 2009 Jul 1;15(13):4467-74. doi: 10.1158/1078-0432.CCR-09-0582. Epub 2009 Jun 16.
9
Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients.三位新的 NY-ESO-1 表位与 DRB1*0803、DQB1*0401 和 DRB1*0901 结合,被 CHP-NY-ESO-1 疫苗接种患者的 CD4 T 细胞识别。
Vaccine. 2010 Jul 19;28(32):5338-46. doi: 10.1016/j.vaccine.2010.05.044.
10
Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes.鉴定一种源自癌-睾丸抗原NY-ESO-1的抗原肽,该肽可与多种HLA-DR亚型结合。
Cancer Immunol Immunother. 2004 Jul;53(7):589-99. doi: 10.1007/s00262-003-0492-6. Epub 2004 Jan 23.

引用本文的文献

1
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1) for the Treatment of NPM1-Acute Myeloid Leukemia.基于针对突变型核磷蛋白(NPM1)的细胞毒性T淋巴细胞的先进治疗药物用于治疗NPM1急性髓系白血病的临床前验证
Cancers (Basel). 2023 May 12;15(10):2731. doi: 10.3390/cancers15102731.
2
Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.针对自身/肿瘤抗原的 T 细胞耐受:癌症患者和健康供体中针对 p53 的自发 CD4+ 而非 CD8+ T 细胞反应。
PLoS One. 2011;6(8):e23651. doi: 10.1371/journal.pone.0023651. Epub 2011 Aug 12.
3
CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤患者对 PASD1 蛋白的 CD4 阳性 T 辅助细胞反应。
Haematologica. 2011 Jan;96(1):78-86. doi: 10.3324/haematol.2010.028241. Epub 2010 Sep 17.
4
Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.肺癌患者中NY-ESO-1免疫升高与降低与自发消退及随后复发的相关性。
Cancer Immun. 2009 Oct 1;9:8.
5
Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells.MAGE-A4肿瘤抗原新型辅助表位的鉴定:Th1细胞增殖的有用工具。
Br J Cancer. 2009 Apr 7;100(7):1135-43. doi: 10.1038/sj.bjc.6604966. Epub 2009 Mar 10.
6
Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1.在NY-ESO-1的一个多反应性HLA II类辅助性T细胞区域内识别天然加工的及与卵巢癌反应性的CD8+ T细胞表位。
Cancer Immunol Immunother. 2008 Aug;57(8):1185-95. doi: 10.1007/s00262-008-0450-4. Epub 2008 Feb 6.
7
Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells.树突状细胞对与人热休克同源蛋白70融合的NY-ESO-1细胞毒性T淋巴细胞表位的交叉呈递
Cancer Sci. 2008 Jan;99(1):107-12. doi: 10.1111/j.1349-7006.2007.00654.x. Epub 2007 Nov 7.

本文引用的文献

1
Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.Th1细胞辅助治疗联合肿瘤疫苗接种:一种促进CTL反应同时避免Tregs积累的新策略。
Int Immunol. 2007 Feb;19(2):151-61. doi: 10.1093/intimm/dxl132. Epub 2006 Dec 22.
2
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.重组痘苗病毒/鸡痘病毒 NY-ESO-1 疫苗可在癌症患者中诱导产生体液和细胞 NY-ESO-1 特异性免疫反应。
Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14453-8. doi: 10.1073/pnas.0606512103. Epub 2006 Sep 19.
3
In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.负载含胆固醇疏水化支链淀粉与NY-ESO-1蛋白复合物的树突状细胞对CD8和CD4 T细胞的体外刺激:一种新的HLA-DR15结合CD4 T细胞表位的鉴定
Clin Cancer Res. 2006 Mar 15;12(6):1921-7. doi: 10.1158/1078-0432.CCR-05-1900.
4
Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.用CTL导向肽进行全身和局部免疫联合局部注射OK-432的抗肿瘤作用
Clin Cancer Res. 2006 Feb 15;12(4):1325-32. doi: 10.1158/1078-0432.CCR-05-1293.
5
An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.在通过1型辅助性T细胞疗法完全清除II类阴性肿瘤组织的过程中,抗原呈递细胞/1型辅助性T细胞间相互作用在引流淋巴结中的重要作用。
Cancer Res. 2006 Feb 1;66(3):1809-17. doi: 10.1158/0008-5472.CAN-05-2246.
6
Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.由HLA-DQ B1 03011递呈的、可被CD4+ T细胞识别的新型NY-ESO-1表位的鉴定。
Int J Cancer. 2006 Feb 1;118(3):668-74. doi: 10.1002/ijc.21391.
7
Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.Toll样受体8介导的CD4 +调节性T细胞功能逆转。
Science. 2005 Aug 26;309(5739):1380-4. doi: 10.1126/science.1113401.
8
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.CD4+ CD25+ 调节性T细胞控制癌症患者抗原特异性CD4+ 辅助性T细胞反应的诱导。
Blood. 2005 Aug 1;106(3):1008-11. doi: 10.1182/blood-2005-02-0607. Epub 2005 Apr 19.
9
Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1.针对肿瘤特异性抗原NY-ESO-1的天然存在与疫苗诱导的CD8+ T细胞反应中不同的结构性TCR库。
J Immunother. 2005 May-Jun;28(3):252-7. doi: 10.1097/01.cji.0000161398.34701.26.
10
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.一种源自NY-ESO-1的表位,它能与多种HLA-DR和HLA-DP4分子发生混杂结合,并刺激来自表达NY-ESO-1的黑色素瘤患者的自体CD4+ T细胞。
J Immunol. 2005 Feb 1;174(3):1751-9. doi: 10.4049/jimmunol.174.3.1751.